An 8-year-old boy with anti-NMDA receptor encephalitis, successfully treated with cyclophosphamide

Tadahiro Mitani; Yoshimitsu Ohtsuka; Kei Yamamoto; Yoshihiro Watanabe; Megumi Tsuji; Kiyoko Samejima; Noriko Aida; Takeshi Sato; Takahito Wada; Hitoshi Osaka

An 8-year-old boy with anti-NMDA receptor encephalitis, successfully treated with cyclophosphamide

Tadahiro Mitani, Yoshimitsu Ohtsuka, Kei Yamamoto, Yoshihiro Watanabe, Megumi Tsuji, Kiyoko Samejima, Noriko Aida, Takeshi Sato, Takahito Wada, Hitoshi Osaka

Research output: Contribution to journal › Article › peer-review

Abstract

We report on an 8-year-old boy with non-paraneoplastic anti-NMDA receptor (NMDAR) encephalitis, who presented with psychotic symptoms and involuntary movement following an intractable seizure. His serum and CSF tested positive for anti-NMDAR antibodies. He received an initial immunotherapy consisting of methylprednisolone pulse therapy (mPSL) and intravenous immunoglobulin therapy (IVIg), without any clinical improvement. He had three cycles of monthly cyclophosphamide pulse therapy (500 mg/m²), and his clinical condition started to improve gradually two weeks after the first cycle, without any side effects. Six months after onset, he tested normal upon standard neurological examination. Cyclophosphamide therapy should be considered for children with anti-NMDAR encephalitis, as well as mPSL and IVIg.

Original language	English
Pages (from-to)	53-57
Number of pages	5
Journal	NO TO HATTATSU
Volume	45
Issue number	1
Publication status	Published - 2013 Jan
Externally published	Yes

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Clinical Neurology

Cite this

@article{830707d562ba4f4fae04cbd020df4731,

title = "An 8-year-old boy with anti-NMDA receptor encephalitis, successfully treated with cyclophosphamide",

abstract = "We report on an 8-year-old boy with non-paraneoplastic anti-NMDA receptor (NMDAR) encephalitis, who presented with psychotic symptoms and involuntary movement following an intractable seizure. His serum and CSF tested positive for anti-NMDAR antibodies. He received an initial immunotherapy consisting of methylprednisolone pulse therapy (mPSL) and intravenous immunoglobulin therapy (IVIg), without any clinical improvement. He had three cycles of monthly cyclophosphamide pulse therapy (500 mg/m2), and his clinical condition started to improve gradually two weeks after the first cycle, without any side effects. Six months after onset, he tested normal upon standard neurological examination. Cyclophosphamide therapy should be considered for children with anti-NMDAR encephalitis, as well as mPSL and IVIg.",

author = "Tadahiro Mitani and Yoshimitsu Ohtsuka and Kei Yamamoto and Yoshihiro Watanabe and Megumi Tsuji and Kiyoko Samejima and Noriko Aida and Takeshi Sato and Takahito Wada and Hitoshi Osaka",

year = "2013",

month = jan,

language = "English",

volume = "45",

pages = "53--57",

journal = "No To Hattatsu",

issn = "0029-0831",

publisher = "Japanese Society of Child Neurology",

number = "1",

}

TY - JOUR

T1 - An 8-year-old boy with anti-NMDA receptor encephalitis, successfully treated with cyclophosphamide

AU - Mitani, Tadahiro

AU - Ohtsuka, Yoshimitsu

AU - Yamamoto, Kei

AU - Watanabe, Yoshihiro

AU - Tsuji, Megumi

AU - Samejima, Kiyoko

AU - Aida, Noriko

AU - Sato, Takeshi

AU - Wada, Takahito

AU - Osaka, Hitoshi

PY - 2013/1

Y1 - 2013/1

N2 - We report on an 8-year-old boy with non-paraneoplastic anti-NMDA receptor (NMDAR) encephalitis, who presented with psychotic symptoms and involuntary movement following an intractable seizure. His serum and CSF tested positive for anti-NMDAR antibodies. He received an initial immunotherapy consisting of methylprednisolone pulse therapy (mPSL) and intravenous immunoglobulin therapy (IVIg), without any clinical improvement. He had three cycles of monthly cyclophosphamide pulse therapy (500 mg/m2), and his clinical condition started to improve gradually two weeks after the first cycle, without any side effects. Six months after onset, he tested normal upon standard neurological examination. Cyclophosphamide therapy should be considered for children with anti-NMDAR encephalitis, as well as mPSL and IVIg.

AB - We report on an 8-year-old boy with non-paraneoplastic anti-NMDA receptor (NMDAR) encephalitis, who presented with psychotic symptoms and involuntary movement following an intractable seizure. His serum and CSF tested positive for anti-NMDAR antibodies. He received an initial immunotherapy consisting of methylprednisolone pulse therapy (mPSL) and intravenous immunoglobulin therapy (IVIg), without any clinical improvement. He had three cycles of monthly cyclophosphamide pulse therapy (500 mg/m2), and his clinical condition started to improve gradually two weeks after the first cycle, without any side effects. Six months after onset, he tested normal upon standard neurological examination. Cyclophosphamide therapy should be considered for children with anti-NMDAR encephalitis, as well as mPSL and IVIg.

UR - http://www.scopus.com/inward/record.url?scp=84872580075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872580075&partnerID=8YFLogxK

M3 - Article

C2 - 23593747

AN - SCOPUS:84872580075

SN - 0029-0831

VL - 45

SP - 53

EP - 57

JO - No To Hattatsu

JF - No To Hattatsu

IS - 1

ER -

An 8-year-old boy with anti-NMDA receptor encephalitis, successfully treated with cyclophosphamide

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this